Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $9,936 | $14,880 | $23,488 | $15,093 |
| % Growth | -33.2% | -36.6% | 55.6% | – |
| Cost of Goods Sold | $2,252 | $2,967 | $0 | $0 |
| Gross Profit | $7,684 | $11,913 | $23,488 | $15,093 |
| % Margin | 77.3% | 80.1% | 100% | 100% |
| R&D Expenses | $108,153 | $111,944 | $99,872 | $76,065 |
| G&A Expenses | $28,282 | $29,299 | $23,036 | $21,325 |
| SG&A Expenses | $28,282 | $29,299 | $23,036 | $21,325 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$105,664 | -$102,434 | $0 | $0 |
| Operating Expenses | $30,771 | $38,809 | $122,908 | $97,390 |
| Operating Income | -$128,988 | -$135,873 | -$99,420 | -$82,297 |
| % Margin | -1,298.2% | -913.1% | -423.3% | -545.3% |
| Other Income/Exp. Net | -$35,586 | $41,219 | $12,862 | -$1,741 |
| Pre-Tax Income | -$164,574 | -$94,654 | -$86,558 | -$84,038 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$164,574 | -$94,654 | -$86,558 | -$84,038 |
| % Margin | -1,656.3% | -636.1% | -368.5% | -556.8% |
| EPS | -5.81 | -7.49 | -13.84 | -18.25 |
| % Growth | 22.4% | 45.9% | 24.2% | – |
| EPS Diluted | -5.81 | -7.49 | -13.84 | -18.25 |
| Weighted Avg Shares Out | 28,326 | 12,632 | 6,253 | 4,605 |
| Weighted Avg Shares Out Dil | 28,326 | 12,632 | 6,253 | 4,605 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,816 | $2,132 | $87 | $426 |
| Interest Expense | $5,127 | $4,134 | $3,907 | $1,792 |
| Depreciation & Amortization | $2,252 | $2,967 | $3,018 | $3,035 |
| EBITDA | -$157,195 | -$87,553 | -$79,633 | -$79,211 |
| % Margin | -1,582.1% | -588.4% | -339% | -524.8% |